| Dr Deanna Lynn Mcdanel, PHARMD, BCPS | |
|
200 Hawkins Dr, University Of Iowa Hospitals And Clinics Cc101 Gh, Iowa City, IA 52242-1009 | |
| (319) 356-2577 | |
| Not Available |
| Full Name | Dr Deanna Lynn Mcdanel |
|---|---|
| Gender | Female |
| Speciality | Pharmacist - Pharmacotherapy |
| Location | 200 Hawkins Dr, Iowa City, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023095023 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P1200X | Pharmacist - Pharmacotherapy | 19513 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Deanna Lynn Mcdanel, PHARMD, BCPS 2190 Dempster Dr, Coralville, IA 52241-9739 Ph: () - | Dr Deanna Lynn Mcdanel, PHARMD, BCPS 200 Hawkins Dr, University Of Iowa Hospitals And Clinics Cc101 Gh, Iowa City, IA 52242-1009 Ph: (319) 356-2577 |
News Archive
The incidence of drug resistance associated with single-dose nevirapine, a drug used to prevent mother-to-child transmission of HIV-1, may be substantially higher than previously thought and of particular risk for those infected with HIV-1 subtype C, according to three new studies published in the July 1 issue of The Journal of Infectious Diseases, now available online.
The outbreak of dengue fever that infected some 20 people in Florida's Martin County late last year unnerved many who feared the tropical disease had once again established a foothold in Florida. The last outbreaks occurred in 2009 and 2010 in Key West—before that, the disease hadn't struck Florida in more than 70 years.
Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart's MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient's own muscle. MyoCell® has been tested successfully on patients in four clinical trials.
Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge.
› Verified 8 days ago
Jess Thompson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 601 Highway 6 W, Iowa City, IA 52246 Phone: 319-338-0581 | |
Kendall Kolk, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-2577 | |
Dr. Thomas Johnston Criswell, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 Hawkins Dr, Pharmaceutical Care, Iowa City, IA 52242 Phone: 319-356-1616 | |
Jodi Langstaff, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2214 Muscatine Ave, Iowa City, IA 52240 Phone: 319-354-2670 | |
Brittany Wright, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 Hawkins Dr, Cc 101 Gh, Iowa City, IA 52242 Phone: 319-356-2577 | |
Patrick Kinn, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-2577 | |
Dr. Holly Flynn, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-2577 |